about
MEK Inhibition Sensitizes Precursor B-Cell Acute Lymphoblastic Leukemia (B-ALL) Cells to Dexamethasone through Modulation of mTOR Activity and Stimulation of AutophagyHypoglycaemic, antioxidative and nephroprotective effects of taurine in alloxan diabetic rabbits.MiR-17-92 represses PTPROt and PP2A phosphatases and amplifies tonic BCR signaling in DLBCL cells.FOXO1 is a TXN- and p300-dependent sensor and effector of oxidative stress in diffuse large B-cell lymphomas characterized by increased oxidative metabolism.FOXO1 activation is an effector of SYK and AKT inhibition in tonic BCR signal-dependent diffuse large B-cell lymphomas.Asparagine synthetase (ASNS) gene polymorphism is associated with the outcome of childhood acute lymphoblastic leukemia by affecting early response to treatment.Microenvironment-induced PIM kinases promote CXCR4-triggered mTOR pathway required for chronic lymphocytic leukaemia cell migration.Increased expression of E3 ubiquitin ligases targeting p53 in CLL patients with wild-type TP53 exhibits associations with clinical features of the disease.Comparison of high-resolution melting analysis with direct sequencing for the detection of recurrent mutations in DNA methyltransferase 3A and isocitrate dehydrogenase 1 and 2 genes in acute myeloid leukemia patients.Role of 657del5 NBN mutation and 7p12.2 (IKZF1), 9p21 (CDKN2A), 10q21.2 (ARID5B) and 14q11.2 (CEBPE) variation and risk of childhood ALL in the Polish population.Polymorphism in IKZF1 gene affects age at onset of childhood acute lymphoblastic leukemiaBRAF inhibition curtails IFN-gamma-inducible PD-L1 expression and upregulates the immunoregulatory protein galectin-1 in melanoma cells
P50
Q28552218-12B7FBEB-5798-42F0-9DCD-08239E83A908Q34867429-8EE980CD-FE90-4D8E-B085-B9502B2A1F23Q38741906-563655EE-4C85-4F90-BCE3-27528C27E3E7Q39806627-78817249-97E0-45A1-83D1-F96EC1D8DE5BQ41111760-9B8D4B19-5419-4EC3-A57F-D68101CEE6B1Q45178025-FF11FAB8-EC60-4075-AFC2-125F13C55A61Q52582842-7D97C46E-8089-422C-967A-38A4D19FA2F8Q53329470-697977E6-334D-4949-9498-54B72BFA8E6DQ53537474-ECEA4629-A30F-4946-BAD0-62A4C9E9A156Q54350836-4C2CB264-B7A0-4624-B5D3-704B73499722Q87405103-CE1F2B68-C845-48F4-BDE1-9EB6DF2ECED0Q93207845-839C0605-AAF3-46F3-999E-7D1FFBF469AA
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-2920-2672
@en
name
Patryk Górniak
@ast
Patryk Górniak
@en
Patryk Górniak
@es
Patryk Górniak
@nl
type
label
Patryk Górniak
@ast
Patryk Górniak
@en
Patryk Górniak
@es
Patryk Górniak
@nl
prefLabel
Patryk Górniak
@ast
Patryk Górniak
@en
Patryk Górniak
@es
Patryk Górniak
@nl
P106
P1153
40461324700
P31
P496
0000-0002-2920-2672